BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today it has entered into an exclusive, worldwide, royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three ...

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March ...

TransCode Therapeutics ( (RNAZ)) has provided an update. On February 5, 2026, TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced that it had submitted an ...

Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com.

BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...

TransCode Therapeutics ( (RNAZ)) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode Therapeutics ( (RNAZ)) just ...

What happens when a trusted tech brand makes a decision that fundamentally alters how its products are used? For Synology, the answer is unfolding in real-time, as its recent move to eliminate ...